PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Ruff, Christian T.
TI  - ENGAGE AF-TIMI 48: Tailoring Edoxaban Dose Preserves Drug Efficacy and Safety
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 25--27
VI  - 14
IP  - 27
4099  - http://mdc.sagepub.com/content/14/27/25.short
4100  - http://mdc.sagepub.com/content/14/27/25.full
AB  - The Effective Anticoagulation With Factor Xa Next Generation in the Atrial Fibrillation—TIMI 48 trial [ENGAGE AF-TIMI 48; Giugliano RP et al. N Engl J Med. 2013] of 21?105 patients with atrial fibrillation and CHADS2 scores =?2 reported the noninferiority of the oral factor Xa inhibitor edoxaban 30 and 60 mg once daily versus warfarin and dose-related decreases in major bleeding. This article presents the results of a subanalysis showing that the protocol-driven dose adjustments in ENGAGE AF maintained the efficacy of edoxaban and reduced bleeding.